InvestorsHub Logo

guardiangel

04/01/14 11:35 AM

#20472 RE: guardiangel #20471

Did someone say there was NO NEWS about Radient? Do the good people on this board really believe that a handful of longs and penny flippers are holding on to 4.75 billion shares of 5 billion authorized? Too funny...2.75 billion since February 2013 have been added to the float and gobbled up..In February 2013..Trademark of DR 70 revised..Patent Renewal..and Shares bought by someone who wants them.. And this gentlemen who has always showed interest to merge and or take over Radient...



hmmm Check this out..Radient is hanging out with the big boys or should we say "Big Pharma"

2013 Analysis of the Global Cancer Diagnostics Market: Emerging Tests, Technology Assessment, Instrumentation Review, Sales Forecasts by Country and Strategic Profiles of Leading Suppliers
Share with Twitter Share with LinkedIn
Share with Repost.us

NEW YORK, Feb. 13, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

2013 Analysis of the Global Cancer Diagnostics Market: Emerging Tests, Technology Assessment, Instrumentation Review, Sales Forecasts by Country and Strategic Profiles of Leading Suppliers

http://www.reportlinker.com/p01095481/2013-Analysis-of-the-Global-Cancer-Diagnostics-Market-Emerging-Tests-Technology-Assessment-Instrumentation-Review-Sales-Forecasts-by-Country-and-Strategic-Profiles-of-Leading-Suppliers.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

This new report from Venture Planning Group provides analysis of the global cancer diagnostics market, including emerging tests, technologies, instrumentation, sales forecasts by country, and strategic profiles of leading suppliers.

Table of Contents I. Worldwide Business Environment

II. Worldwide Market Structure

III. Major Current And Emerging Cancer Diagnostic Tests

1. Introduction2. Tumor Marker Classification3. ACTH4. Alpha-Fetoprotein (AFP)5. Beta-2 Microglobulin6. CA 15-3/27.297. CA 19-98. CA-1259. Calcitonin10. Carcinoembrionic Antigen (CEA)11. Estrogen and Progesterone Receptors12. Ferritin13. Gastrin14. Human Chorionic Gonadotropin (HCG)15. Insulin16. NSE17. Occult Blood18. PAP Smear/HPV19. Prostatic Acid Phosphatase (PAP)20. Prostate-Specific Antigen (PSA)21. Squamous Cell Carcinoma Antigen (SCC)22. T and B Lymphocytes23. TdT24. Thyroglobulin25. Tissue Polypeptide Antigen (TPA)26. Biochemical Tumor Markers- ADA- B-Protein- PNP- 5'-Nucleotidase 27. Oncogenes- Abl/abl-bcr- AIB1- BCL-2- BRCA1- CD44- C-fos- C-myb- C-myc- CYP-17- Erb-B- HPC1- N-myc- P40- P51- P53- PIK3CA- PTI-1- Ras- Reg- Sis- Src28. Polypeptide Growth Factors- Basic Fibroblast Growth Factor- Beta-TGF- Cachectin (TNT)- Calmodulin- ECFR- Nerve Growth Factor (NGF)- Epidermal Growth Factor (EGF)- Ornithine Decarboxylase- Transferrin- Transforming Growth Factor-Alpha 29. Ectopic Hormones30. Colony Stimulating Factors31. Lymphokines- Alpha-Interferon- B Cell Growth Factors- B Cell Growth Factor (BCGF)- Gamma-Interferon- Interleukin-1 (IL-1)- Macrophage Activating Factor32. Immunohistochemical Stains33. Emerging Tumor Markers- N-Acetylglucosamine- Actin- Alpha-Actin - Antineuronal Antibodies- 7B2- B72.3- Bax- BCD-F9- BLCA-4- Blood Group Antigens A,B,H- CA 50- CA 72-4/TAG-72- CA 195- CA-242- CA-549- CAM 26- CAR-3- Cathepsin-D- Chromogranin A and B- Cluster 1 Antigen- Cluster-5/5A Antigen- CTA- CU18- DR-70- DU-PAN-2- Endometrial Bleeding Associated Factor- Endostatin- Epithelial Membrane Antigen- Feulgen Hydrolysis- Fibronectin- FSH- (1->3)-L-fucosyltransferase- Gastrin-Releasing Peptide (GRP)- GDCFP-15- Glucagon- Glycoamines- H23- Her-2- Human Carcinoma Antigen- HPA- HSP27- Intermediate Filaments- Cytokeratins/CK18/Cyfra 21-1- Desmin- Gliofibrillary Acid Protein- Neurofilaments- Vimentin- KA 93- Kinases- KP16D3- LAI- Leukocyte Common Antigen- Lewis Antigens- Lysophosphatidic Acid (LPA)- Ma 695/Ma 552- MABDF3- MAG- ME1- Minactivin- MN/CA9- MSA- Mucin Cancer Antigen (MCA)- Multiple Tumor Suppressor 1- Myosin- NEA-130- NMP22- OA-519- Opiod Peptides- P-glycoprotein- Pancreatic Oncofetal Antigen (POA)- Placental Lactogen- PR92- Proliferative Index, Ki-67- Px- RB Inactivation/Deletion- Ret- SCCL 175- Selectin- Sialic Acid- Sialyl SSEA-1/SLX- SN10- Somatostatin- TA-90- TABA- Tachykinin- TAG 12- TPS- Troponin- Tubulin- VCAM- VEGF- Villen

IV. Instrumentation Review:

Leading Analyzers Marketed by Abbott, Beckman Coulter/Danaher, Binding Site, bioMerieux, Carolina Chemistries, DiaSorin, Horiba, Inverness/Alere, J&J, Olympus, Roche, Siemens, Tosoh, Vital Diagnostics and other suppliers

V. Current and Emerging Technologies

1. Monoclonal and Polyclonal Antibodies2. Immunoassaysa. Technological Principleb. Radioimmunoassay (RIA)c. Enzyme Immunoassays (EIA)- Overview- ELISA- Immunofiltration- Particle-Membrane Capture Immunoassay- Enzyme Amplificationd. Fluorescent Immunoassayse. Luminescence- Chemiluminescence- Bioluminescencef. Latex Agglutinationg. ImmunoprecipitationH. Affinity Chromatographue. Liposome Flow-Injection Immunoassay3. Molecular Diagnosticsa. Technology Overviewb. Amplification Methods- PCR- DAP-PCR- Immuno-PCR- QC-PCR- CAR- DNA- HPA- LCR- NASBA- QBR- SDA- 3 SR, and others4. Chromosome Analysisa. Chronic Myelogenous Leukemia (CML)b. Acute Myeloid Leukemia (AML)c. Acute Lymphoblastic Leukemia (ALL)d. Malignant Lymphomas Lymphoid Malignanciese. Chronic Lymphocytic Leukemia (CLL)f. Solid Cancersg. Chromosomal Translocation and Oncogenes5. Artificial Intelligence6. Flow Cytometry7. Two Dimensional Gel Electrophoresis (2-DGE)8. Biosensors9. Competing/Complementing Technologiesa. CTb. MRIc. NMRd. PETe. Photonics Spectroscopy

VI. Competitive Profiles

- Abbott- AdnaGen- Applied Gene Technologies- Beckman Coulter/Danaher- Becton Dickinson- Biomedical Diagnostics- bioMerieux- Bio-Rad- CellSearch- Cepheid- Dako- Decode- Diadexus- Diagnocure- Diasorin- Eiken Chemical- Enterix- Enzo Biochem- Epigenomics- Exact Sciences- Fujirebio- Gen-Probe- Guided Therapeutics- Hologic- Kreatech- Kyowa Medex- Life Technologies- Mackay Life Sciences- Myriad Genetics- Nanogen Elitech- Nuvelo- OncoLab- Ortho-Clinical Diagnostics- Panacea Pharmaceuticals- Polartechnics- Polymedco- PreMD- Qiagen/Ipsogen- Radient Pharmaceuticals- Roche- Scienion- Sequenom- Siemens Healthcare- Takara Bio- Targeted Diagnostics & Therapeutics- Tosoh - Vermillion/Correlogic Systems- Wako Pure Chemicals- Wallac/PE- Zila

Appendixes: Major Universities and Research Centers Developing

Cancer Diagnostic Technologies and Applications

List of Tables

Tumor Marker Classification

Major Companies Developing or Marketing

ACTH Tests

Major Companies Developing or Marketing

AFP Tests

Major Companies Developing or Marketing

Beta-2 Microglobulin Tests

Major Companies Developing or Marketing

CA 15-3/27.29 Tests

Major Companies Developing or Marketing

CA 19-9 Tests

Major Companies Developing or Marketing

CA 125 Tests

Major Companies Developing or Marketing

Calcitonin Tests

Major Companies Developing or Marketing

CEA Tests

Major Companies Developing or Marketing

Estrogen Receptor Tests

Major Companies Developing or Marketing

Progesterone Receptor Tests

Major Companies Developing or Marketing

Ferritin Tests

Major Companies Developing or Marketing

Gastrin Tests

Major Companies Developing or Marketing

HCG Tests

Major Companies Developing or Marketing

Insulin Tests

Major Companies Developing or Marketing

NSE Tests

Major Companies Developing or Marketing

Occult Blood Tests

Major Companies Developing or Marketing

PAP Smear/HPV Tests

Major Companies Developing or Marketing

PAP Tests

Major Companies Developing or Marketing

PSA Tests

Major Companies Developing or Marketing

Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications

In Cancer Diagnosis

Oncogenes Potential Applications

In Cancer Diagnosis

Major Companies Developing or Marketing

Oncogene Tests

Growth Factors Potential Applications

In Cancer Diagnosis

Colony Stimulating Factors Potential

Applications in Cancer Diagnosis

Lymphokines Potential Applications

In Cancer Diagnosis

Immunohistochemical Stains Potential

Applications in Cancer Diagnosis

Worldwide, All Market Segments, Laboratories

Performing Cancer Diagnostic Testing By Country

Worldwide, All Market Segments, Cancer Diagnostic

Test Volume Forecasts By Country

Worldwide, All Market Segments, Cancer Diagnostics

Sales Forecasts By Country

To order this report:In_Vitro_Diagnostic Industry:

2013 Analysis of the Global Cancer Diagnostics Market: Emerging Tests, Technology Assessment, Instrumentation Review, Sales Forecasts by Country and Strategic Profiles of Leading Suppliers

http://www.prnewswire.com/news-releases/2013-analysis-of-the-global-cancer-diagnostics-market-emerging-tests-technology-assessment-instrumentation-review-sales-forecasts-by-country-and-strategic-profiles-of-leading-suppliers-191069911.html

lakeshore555

04/01/14 11:51 AM

#20473 RE: guardiangel #20471

The debt is most certainly NOT paid off.

Yes, the lender agreed to a debt-for-equity swap. So please explain how shares converted at a SP under 0.0001 can pay off $14 million debt, starting in December 2011, when there are only 5 billion shares in the A/S? That is only $500,000 of the $14 million, AT BEST.

All we have is conjecture because this company stopped filing with the SEC, does not have an office to visit, does not answer phone calls or emails, and does not have an IR Department. If your reasoning tells you that this company is being taken over and resurrected, fine, buy all the shares you can get. It's a once-in-a-lifetime dream jackpot, if what you are saying is true.

Curious, though, that only two people believe the takeover rumor, and they apparently already have all the shares they want, because nobody is buying and everybody else is selling.

Gold Seeker

04/01/14 11:58 AM

#20475 RE: guardiangel #20471

From the last 10k on debt.

"As of June 15, 2012, we had the following approximate amounts of outstanding short term indebtedness:



· Accrued interest of approximately $1,054,088;



· Approximately $46,000 in unsecured convertible notes bearing interest at 10% per annum increased to 18% per annum due to failure to pay the Notes by September 29, 2010;



· Approximately $25,000 in senior unsecured convertible promissory notes bearing interest at 18% interest, payable quarterly in cash, which became due between December 2010 and May 2011;



· Approximately $8.0 million in legal settlement promissory notes, bearing interest at 8% per annum. We are obligated to retire the Notes in monthly installments, commencing January 31, 2012, by payment in cash or (at our sole option) by delivery of shares of our common stock in an amount equal to 6.25% of the initial principal amount of each Note, plus accrued interest;



· Approximately $4.8 million in outstanding November Notes and $3.4 million in Series B and $500,000 Series C convertible preferred stock which, unless converted into our common stock, matures or is subject to mandatory redemption on November 29, 2012; and




· Approximately $300,000 in unsecured convertible notes bearing interest at 4% per annum that matures on April 30, 2015.



Absent full conversion of these debts or the receipt of new financing or series of financings, our current operations do not generate sufficient cash to pay these obligations, when due. Accordingly, there can be no assurance that we will be able to pay these or other obligations which we may incur in the future.



In the event we are unable to convert into equity the balance of the outstanding November Notes, RDO Notes and the outstanding redeemable Series B and Series C Preferred Stock, the holders may obtain judgments against us and seek to enforce such judgments against our assets, in which event we will be required to cease our business activities and the equity of our stockholders will be effectively wiped out."


dcspka

04/01/14 12:34 PM

#20479 RE: guardiangel #20471

Thank you for a very comprehensive outline of the "supposed" debt overhang that lakeshore keeps falling back on.

I also choose E..The Lenders, creeping Takeover Group and a Handful of Longs own the shares to RXPC- just waiting on the last of the patent information, Dignyte reverse merger news, and finalization of lawsuit to come to fruition. All of this will occur in relative tandem for remaining Long Investors